Hematoporphyrin derivative-mediated photodynamic therapy inhibits tumor growth in human cholangiocarcinoma in vitro and in vivo

Hepatology Research

Volumn 39, Issue 12, 2009, Pages 1190-1197

  Cao, Liang qi ^a   Xue, Ping ^a   Lu, Hai wu ^a   Zheng, Qiang ^a   Wen, Zi long ^a   Shao, Zhi jian ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cholangiocarcinoma; Hematoporphyrin derivative; Photodynamic Therapy

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; HEMATOPORPHYRIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MITOSIS; MOUSE; NONHUMAN; NUDE MOUSE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 73849151875     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00569.x     Document Type: Article

References (30)

1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney D.M. Biliary tract cancers. N Engl J Med 1999; 341: 1368-78.
2. Blechacz B, Gores G.J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48: 308-21.
3. Sandhu DS, Roberts L.R. Diagnosis and management of cholangiocarcinoma. Curr Gastroenterol Rep 2008; 10: 43-52.
4. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer R.M. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98: 873-5.
5. Khan SA, Toledano MB, Taylor-Robinson S.D. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 10: 77-82.
6. Dumoulin FL, Gerhardt T, Fuchs S et al. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc 2003; 57: 860-7.
7. Ortner MA, Dorta G. Technology insight: photodynamic therapy for cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 459-67.
8. Witzigmann H, Berr F, Ringel U et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 2006; 244: 230-9.
9. Wiedmann M, Berr F, Schiefke I et al. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc 2004; 60: 68-75.
10. Kiesslich T, Krammer B, Plaetzer K. Cellular mechanisms and prospective applications of hypericin in photodynamic therapy. Curr Med Chem 2006; 13: 2189-204.
11. Abels C. Targeting of the vascular system of solid tumours by photodynamic therapy (PDT). Photochem Photobiol Sci 2004; 3: 765-71.
12. Chekulayeva LV, Chekulayev VA, Shevchuk I.N. Active oxygen intermediates in the degradation of hematoporphyrin derivative in tumor cells subjected to photodynamic therapy. J Photochem Photobiol B 2008; 93: 94-107.
13. Wainwright M. Photodynamic therapy: the development of new photosensitisers. Anticancer Agents Med Chem 2008; 8: 280-91.
14. Chekulayeva LV, Shevchuk IN, Chekulayev VA, Ilmarinen K. Hydrogen peroxide, superoxide, and hydroxyl radicals are involved in the phototoxic action of hematoporphyrin derivative against tumor cells. J Environ Pathol Toxicol Oncol 2006; 25: 51-77.
15. Maier A, Tomaselli F, Matzi V, Rehak P, Pinter H, Smolle-Jüttner F.M. Photosensitization with hematoporphyrin derivative compared to 5-aminolaevulinic acid for photodynamic therapy of esophageal carcinoma. Ann Thorac Surg 2001; 72: 1136-40.
16. Stukavec J, Horak L, Duchac V et al. Comparison of photodynamic therapy with phthalocyanine and photofrin in human colorectal carcinoma. Neoplasma 2008; 55: 127-9.
17. Corti L, Toniolo L, Boso C et al. Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma. Lasers Surg Med 2007; 39: 394-402.
18. Keeley SB, Pennathur A, Gooding W, Landreneau RJ, Christie NA, Luketich J. Photodynamic therapy with curative intent for Barrett's esophagus with high grade dysplasia and superficial esophageal cancer. Ann Surg Oncol 2007; 14: 2406-10.
19. Litle VR, Christie NA, Fernando HC, Buenaventura PO, Ferson PF, Luketich J.D. Photodynamic therapy for endobronchial metastases from nonbronchogenic primaries. Ann Thorac Surg 2003; 76: 370-5.
20. Jichlinski P. Photodynamic applications in superficial bladder cancer: facts and hopes!. J Environ Pathol Toxicol Oncol 2006; 25: 441-51.
21. Allison RR, Bagnato VS, Cuenca R, Downie GH, Sibata C.H. The future of photodynamic therapy in oncology. Future Oncol 2006; 2: 53-71.
22. Ortner M.A. Photodynamic therapy in cholangiocarcinomas. Best Pract Res Clin Gastroenterol 2004; 18: 147-54.
23. Ortner MA, Liebetruth J, Schreiber S et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998; 114: 536-42.
24. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann J.F. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100: 2426-30.
25. Wiedmann M, Caca K, Berr F et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer 2003; 97: 2783-90.
26. Ferrario A, Fisher AM, Rucker N, Gomer C.J. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 2005; 65: 9473-8.
27. Chekulayeva LV, Shevchuk IN, Chekulayev V.A. Influence of temperature on the efficiency of photodestruction of Ehrlich ascites carcinoma cells sensitized by hematoporphyrin derivative. Exp Oncol 2004; 26: 125-39.
28. Zhu Y, Hoell P, Ahlemeyer B, Krieglstein J. PTEN: a crucial mediator of mitochondria-dependent apoptosis. Apoptosis 2006; 11: 197-207.
29. Date M, Fukuchi K, Morita S, Takahashi H, Ohura K. 15-deoxy-delta 12,14-prostaglandin J2, a ligand for peroxisome proliferators-activated receptor- gamma, induces apoptosis in human hepatoma cells. Liver Int 2003; 23: 460-6.
30. Cao LQ, Chen XL, Wang Q et al. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells Acta Pharmacol Sin 2007; 28: 879-87.